Your browser is no longer supported. Please, upgrade your browser.
CEMI [NASD]
Chembio Diagnostics, Inc.
Index- P/E- EPS (ttm)-1.34 Insider Own8.82% Shs Outstand20.16M Perf Week-4.97%
Market Cap67.37M Forward P/E- EPS next Y-0.77 Insider Trans0.00% Shs Float17.38M Perf Month-13.10%
Income-25.50M PEG- EPS next Q-0.27 Inst Own43.90% Short Float12.83% Perf Quarter-55.17%
Sales32.50M P/S2.07 EPS this Y-65.80% Inst Trans0.98% Short Ratio0.42 Perf Half Y-27.46%
Book/sh1.38 P/B2.36 EPS next Y18.30% ROA-33.70% Target Price- Perf Year-74.06%
Cash/sh1.11 P/C2.92 EPS next 5Y25.00% ROE-75.10% 52W Range3.01 - 13.33 Perf YTD-31.58%
Dividend- P/FCF- EPS past 5Y-40.00% ROI-49.00% 52W High-75.62% Beta1.86
Dividend %- Quick Ratio2.20 Sales past 5Y6.00% Gross Margin26.50% 52W Low7.97% ATR0.25
Employees355 Current Ratio3.20 Sales Q/Q47.80% Oper. Margin-61.00% RSI (14)35.59 Volatility7.60% 6.59%
OptionableYes Debt/Eq0.67 EPS Q/Q-55.50% Profit Margin-68.60% Rel Volume0.07 Prev Close3.22
ShortableYes LT Debt/Eq0.66 EarningsMay 06 AMC Payout- Avg Volume5.31M Price3.25
Recom2.00 SMA20-11.71% SMA50-18.45% SMA200-34.99% Volume371,960 Change0.93%
Dec-03-20Upgrade Craig Hallum Hold → Buy $5 → $10
Nov-06-20Upgrade Colliers Securities Neutral → Buy $7.50
Jun-17-20Downgrade The Benchmark Company Speculative Buy → Hold
Jun-17-20Downgrade Craig Hallum Buy → Hold
Jun-17-20Downgrade Canaccord Genuity Buy → Hold $7
May-26-20Initiated Robert W. Baird Outperform $21
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $6
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $5
Dec-19-18Initiated Dougherty & Company Buy
Aug-11-16Reiterated The Benchmark Company Speculative Buy $10 → $9
Apr-18-16Reiterated The Benchmark Company Speculative Buy $6 → $8
Nov-04-15Initiated The Benchmark Company Speculative Buy $6
Sep-10-13Resumed The Benchmark Company Speculative Buy $7
May-06-21 04:05PM  
02:30PM  
Apr-22-21 08:00AM  
Apr-07-21 02:51AM  
Apr-05-21 01:35PM  
11:43AM  
Apr-01-21 05:30PM  
Mar-11-21 04:05PM  
02:30PM  
Mar-10-21 10:13AM  
Mar-08-21 08:00AM  
Feb-25-21 04:05PM  
Feb-03-21 12:23AM  
Jan-14-21 07:00AM  
Dec-17-20 04:05PM  
Dec-05-20 02:15AM  
Dec-04-20 08:49AM  
Dec-03-20 08:48AM  
Dec-02-20 01:22PM  
Nov-27-20 01:10PM  
Nov-13-20 04:40PM  
Nov-05-20 04:05PM  
02:30PM  
Oct-23-20 08:00AM  
Oct-16-20 07:15AM  
Oct-15-20 05:55PM  
Oct-06-20 08:38AM  
Oct-02-20 10:10AM  
07:26AM  
Sep-25-20 08:55AM  
Sep-08-20 06:00PM  
Aug-25-20 08:57AM  
Aug-17-20 02:15PM  
11:50AM  
11:40AM  
11:01AM  
07:30AM  
06:55AM  
Aug-16-20 03:09PM  
11:44AM  
10:51AM  
Aug-15-20 02:35PM  
Aug-14-20 03:55PM  
02:25PM  
01:00PM  
12:00PM  
10:00AM  
09:31AM  
08:30AM  
Aug-13-20 07:40PM  
06:10PM  
02:25PM  
01:45PM  
12:45PM  
11:31AM  
10:30AM  
09:47AM  
Aug-12-20 04:45PM  
04:11PM  
04:10PM  
03:27PM  
03:15PM  
02:40PM  
12:35PM  
11:59AM  
09:26AM  
Aug-11-20 07:15PM  
11:00AM  
Aug-10-20 10:01PM  
08:35PM  
07:42PM  
06:11PM  
03:05PM  
01:59PM  
01:35PM  
12:50PM  
12:38PM  
11:30AM  
06:20AM  
Aug-08-20 08:01PM  
Aug-07-20 08:24PM  
07:13PM  
02:15PM  
01:15PM  
Aug-06-20 04:10PM  
04:05PM  
12:15PM  
11:09AM  
06:20AM  
Aug-05-20 11:58PM  
03:35PM  
11:30AM  
06:20AM  
Aug-04-20 01:26PM  
11:30AM  
10:16AM  
08:30AM  
Aug-03-20 09:58PM  
08:15PM  
05:45PM  
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, Hepatitis C, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, Rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.